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Keywords: Meningococcal disease; Epidemiology; Vaccine; ImmunizationA B S T R A C TInvasive meningococcal disease (IMD) caused by Neisseria meningitidis is associated with high morbidity and
mortality. Although IMD incidence is highest in infants, a second peak occurs in adolescents/young adults.
The incidence of IMD and the predominant disease-causing meningococcal serogroups vary worldwide.
Epidemiologic data have guided the development of meningococcal vaccines to reduce the IMD burden. In
Europe, serogroup C IMD has been substantially reduced since the introduction of a serogroup C conjugate
vaccine. Serogroup B predominates in Europe, although cases of serogroup Y IMD have been increasing in
recent years. In the United States, declines in serogroup C and Y disease have been observed in association
with the introduction of quadrivalent (serogroups ACWY) meningococcal conjugate vaccines; serogroup B
persists and is now the most common cause of outbreak associated disease. In the African meningitis belt, a
conjugate vaccine for serogroup A has been effective in decreasing meningitis associated with that serogroup.
Outbreaks of the previously rare serogroup X disease have been reported in this region since 2006. In recent
years, outbreaks of serogroup B IMD, for which vaccines have only recently been approved by the U.S. Food
and Drug Administration and the European Medicines Agency, have occurred in Europe and the United
States. Targeting meningococcal vaccination to adolescents/young adults may reduce the morbidity and
mortality associated with IMD and has the potential to impact the larger community through herd beneﬁts.
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http://dx.doi.org/10.1016/j.jadohealth.2016.04.012Invasivemeningococcal disease (IMD) is a condition, too often
fatal, caused by invasion of the bacterium Neisseria meningitidis
into the blood stream and subsequent development of septic
shock and purpura fulminans in a subset of patients. When the
bacterium gains access to the central nervous system, meningitisresults. The morbidity and mortality resulting from either con-
dition is substantial, with a case-fatality rate (CFR) approxi-
mating 10% in developed countries [1e3]. Many survivors
experience permanent debilitating sequelae such as hearing loss,
neurologic impairments, or limb loss [3,4]. The incidence of IMD
varies by geographic region and ranges from <.5 to .9 cases per
100,000 population in North America and Europe to 10 to 1,000
cases per 100,000 population in the African meningitis belt.
Incidence is highest in infants and young children, with a second
smaller peak in adolescents and young adults (Figure 1) [8,9].
Colonization of the nasopharynx is a prerequisite for IMD, and
humans are the only host for this organism. Colonization is
typically asymptomatic; however, N. meningitidis can translocate
from the nasopharynx to the blood stream, resulting in disease.
Transmission may occur following close contact with an infected
or colonized individual.
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Figure 1. Universality of meningococcal epidemiology: highest incidence in infancy with second peak during adolescence (all serogroups). (A) Invasive meningococcal
disease in the United States, 1998e2007, cases per 100,000 population [5]; (B) invasive meningococcal disease in Europe after introduction of MenCC, 2011; cases per
100,000 population [6]; (C) meningococcal meningitis in Burkina Faso after introduction of MACV, 2011, cases per 100,000 population [7].
S.I. Pelton / Journal of Adolescent Health 59 (2016) S3eS11S4N. meningitidis is a gram-negative diplococcus in which most
pathogenic isolates are encapsulated [10,11]. The major catego-
rization of N. meningitidis is by capsular polysaccharide
serogroup, of which there are 13. Most cases of IMD are caused by
serogroups A, B, C, W-135 (referred to as serogroup W herein),
X, and Y [12], with serogroup prevalence differing according
to geographic region (Figure 2). A more detailed molecular
characterization scheme termed multilocus sequence typing is
derived from the analysis of seven housekeeping genes and
groups isolates into sequence types and sets of related sequence
types called clonal complexes [14,15]. The ability to characterize
strains by multilocus sequence typing and sequence types is
important for characterizing outbreaks to determine if they are
due to a single strain circulating within the community and for
identiﬁcation of hypervirulent strains.
Because of rapid bacterial multiplication in the bloodstream
and the subsequent progression of disease, immediate antibiotic
treatment and hospital admission with supportive care ofpatients is required when IMD is suspected [16]. In addition to
antibiotic prophylaxis for secondary prevention in close contacts,
vaccination may also be of value in controlling meningococcal
outbreaks [17]. Effective vaccines are available for serogroups A,
C, W, and Y [18], and vaccines for serogroup B (MnB) have
recently been approved [19].
Although it is well documented that infants experience high
rates of IMD, meningococcal carriage rates in infants in western
countries are relatively low, rising as high as 25%e33% by young
adulthood in the United Kingdom [20,21]. In the African men-
ingitis belt, carriage rates are highest in individuals aged
5e14 years (5%) [22]. Although carriage isolates are genetically
heterogeneous in nature, isolates that cause IMD usually repre-
sent a subset of those carried [14]. The properties that make
these hyperinvasive strains more pathogenic have not yet been
completely identiﬁed, but it has been postulated that the pres-
ence of viral genetic material incorporated and expressed by
N. meningitidis (a bacterial prophage) [23,24] may be a virulence
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Figure 2. Predominant serogroups associated with invasive meningococcal disease worldwide [13].
S.I. Pelton / Journal of Adolescent Health 59 (2016) S3eS11 S5factor. As well, host genetic factors [25] may contribute to sus-
ceptibility to disease.
Introduction of serogroup-speciﬁc vaccines for N. meningitidis
has been shown to reduce the prevalence of IMD. To maximize
the beneﬁt of these vaccines, it is imperative to understand the
local epidemiology of IMD in speciﬁc geographic areas where
they will be used. A number of recent articles have examined the
epidemiology of IMD globally [12,26] and in individual countries
[1,27e33]. However, meningococcal epidemiology evolves over
time due to secular trends and vaccine pressure. It is the intent of
this supplemental review article to present the most recent
epidemiologic data and to assess the changes that have occurred
since the introduction of meningococcal vaccines.
Invasive Meningococcal Disease by Geographic Region
United States
In theUnitedStates, thequadrivalentACWYvaccine(MenACWY)
was recommended by the Advisory Committee on Immunization
Practices (ACIP) of the Centers for Disease Control and Prevention
in 2005 for individuals aged 11e12 years [34]. A 2011 update from
ACIP recommended administration of a booster dose at age 16 [35].
In the United States, ACIP also recommended (in 2015) an MnB
vaccine serieswhichmaybeadministered toadolescents andyoung
adults aged 16 through 23 years to provide short-term protection
against most strains causing serogroup B meningococcal disease;
the preferred age for vaccination is 16 through 18 years [36]. ACIP
also recommends vaccination with an MnB vaccine in at-risk
persons aged 10 years and older [19]. Currently approved MnB
vaccines in the United States are bivalent rLP2086 (Trumenba;
MenB-FHbp) and 4CMenB (Bexsero; MenB-4C).
Even before the recommendation for universal immunization
of adolescents with meningococcal vaccines, the rate of IMD
in the United States began to steadily decrease in the year 2000
after a high in 1999 of 1.1 per 100,000 population (Figure 3).A comparison of periods before (2000e2005) and after
(2006e2010) the introduction of the quadrivalent vaccine found
that serogroups B, C, and Y were most frequently associated with
IMD both before and after MenACWY introduction [39]. In the
most recent reporting year (2013), 556 cases of meningococcal
disease were reported to the National Notiﬁable Disease Sur-
veillance System (.18 cases/100,000 population); serogroup B and
C accounted for most cases [37]. Although the genetic composi-
tion of isolates varied, strains of N. meningitidis from cases of IMD
before and after the introduction of universal adolescent immu-
nization with meningococcal quadrivalent vaccine remained
genetically similar [39]. There was evidence of capsule switching
(strains with genetic markers that were previously associated
with one capsule type now found with a different capsule type)
during both periods. Outbreaks of meningococcal disease (mul-
tiple cases due to the same strain of N. meningitidis in the same
“community”) account for approximately 2% of cases; in the last
4 years, outbreaks on college campuses have been reported pri-
marily due to serogroup B and in the men having sex with men
communities primarily due to serogroup C [40,41]. Data suggest
that infection with inﬂuenza virus may be a predisposing factor
for the development of IMD because seasonal peaks in IMD
routinely occurred 2 weeks after peaks in hospitalization for
inﬂuenza [42]. This suggests that increased use of inﬂuenza
vaccines in the United States may also impact IMD incidence.
Between 2003 and 2013, the rate of meningococcal menin-
gitis decreased from .61 per 100,000 to .18 per 100,000 in the
United States [37]. Data from National Vital Statistics Reports
indicate that deaths from meningococcal infection have
decreased almost every year between 1997 (309 deaths) and
2013 (59 deaths) (Figure 3) [38].
Europe
As in the United States, many European countries have seen
reductions in IMD cases in recent years. For example, substantial
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Figure 3. Incidence and deaths from meningococcal disease in the United States. Incidence data per 100,000 population from the National Notiﬁable Diseases
Surveillance System [37]. Deaths from meningococcal disease from the National Vital Statistics System [38].
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(from 4.5 to .6 per 100,000 population between 2001 and 2012)
[43], Germany (from .94 to .47 per 100,000 population between
2003 and 2010) [44], and England and Wales (from 5.37 to 2.21
per 100,000 population between 1998/1999 and 2008/2009)
[45]. Among the combined 29 European Union countries
reporting surveillance data, the rate of IMD cases dropped from
1.9 per 100,000 population in 1999 to 1.1 per 100,000 population
in 2007 [46]. Recently, however, an increase in IMD has been
reported in Sweden, as cases rose from .6 per 100,000 population
in 2010 to .95 per 100,000 population in 2012 [47].
In Europe, serogroups B and Cwere responsible for most cases
of IMD at the beginning of the 21st century [43]. Because of an
increased number of cases and deaths seen in the 1990s, a con-
jugate vaccine for N. meningitidis serogroup C (MenCC) was
approved in the United Kingdom in 1999 [48], followed by
incorporation of this vaccine into the national immunization
programs (NIPs) of a number of other European countries [49].
Consequent reductions in IMD cases associated with serogroup C
occurred in all countries where MenCC was used [50], and cases
of IMD associated with serogroup C have proportionately
decreased in the years following MenCC introduction [46]. Thus,
as of 2011, serogroup B remains themost prominent cause of IMD
among most countries of Europe (73.6% of IMD cases) with
serogroup C associated with only 14.4% of cases [6]. In recent
years, the proportion of serogroup Y IMD cases has increased in a
number of European countries. In particular, in 2013, the Scan-
dinavian countries (with the exception of Denmark) all had
proportions of serogroup Y IMD greater than 10% of all IMD cases
in which the serogroup was determined. In Sweden, serogroup Y
was the predominant serogroup from 2011 to 2013, with
approximately 50% of serogrouped IMD cases caused by
serogroup Y each year [51]. During this period, the incidence of
IMD was .6 per 100,000 population in 2010 and 2011 and rose to
.95 per 100,000 population in 2012 [47]. In England and Wales,
although the overall incidence of IMD declined between 2007
and 2009, the proportion of cases caused by serogroup Y
increased each year [52]. The increase in serogroup Y cases in
Europe may be partially due to the preferential use of MenCC as
opposed to the quadrivalent serogroup ACWY vaccine. Although
neither serogroup A nor serogroup W cause an appreciable
number of IMD cases in Europe [6], the incidence of serogroupW
disease has been increasing in England and Wales since 2009
[53]. In 2013/2014 serogroup W was associated with 15% of IMD
cases [53]. In response to this increase, the Joint Committee on
Vaccination and Immunisation of Public Health England has
recommended that individuals aged 14e18 years be vaccinatedwith the quadrivalent conjugate ACWY vaccine with the goal of
generating herd immunity in the overall population against
serogroup W disease [54]. In 2007, 23% of IMD cases in Europe
weremeningitis and 23%were septicemia (of a total of 5,491 IMD
cases), with 11% being both meningitis and septicemia and 42%
being of unknown clinical presentation [46]. In 2011, there were
proportionately more meningitis and septicemia cases (43% and
33%, respectively, of a total of 1,824 IMD cases), with 18% being
meningitis and septicemia. The apparent increases may actually
be the result of more complete reporting as there were no cases
classiﬁed as “unknown” for that year [6].
The CFR in Europe was 8.1% in 2007 and varied considerably
among the reporting countries. The highest CFRs in 2007 were in
Hungary (16.3% of 43 IMD cases) and Poland (14.0% of 335 IMD
cases) [46]. In 2011, the CFR in Europe was 8.7%, with the highest
rates occurring in Slovakia (40.0% of 20 cases) and Hungary
(17.9% of 67 cases) [6].
Latin America
The incidence of IMD varies among the Latin American
countries, with incidence rates ranging from .6 per 100,000 in
Argentina (1990e2003) and Chile (2009) to 3.4 per 100,000 in
Uruguay (Canelones, 2001e2002) [55]. Because of the large
geographic area that encompasses Latin America, the predomi-
nant serogroups that cause IMD vary by location. Serogroup C has
been predominant in the regions of Mexico, Central America, the
Caribbean, and Brazil, whereas serogroup B has predominated in
the Andean region and the Southern Cone region (Argentina,
Chile, and Uruguay) [56]. However, evenwithin a country as large
as Brazil, serogroup C has recently been the most common
serogroup associatedwith IMD across internal regions, gaining in
prominence (Federal District) or overtaking serogroup B (Ama-
zonas) [33,57]. Recently, there has been an increase in cases of
serogroup W IMD reported in the Southern Cone [58]. In Brazil
and Argentina, an increased percentage of IMD cases has been
caused by serogroup W since the mid-2000s [58]. In Chile, the
percentage of serogroup W IMD cases has increased every year
between 2009 (1.8%) and 2012 (58.3%), and it is now the pre-
dominant serogroup in that country [59]. Increases in the per-
centage of serogroup W IMD cases between 2010 and 2011 were
observed in the <1-year (25% vs. 62.5%) and >20-year (6.6% vs.
27.7%) age groups [60]. Most of the serogroupW isolates in South
America belong to single sequence type [57], similar to the
virulent strains identiﬁed in Hajj pilgrims in 2000 [60].
Currently, meningococcal vaccines are rarely included in the
NIPs in Latin American countries. The exceptions are Cuba,which,
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tion serogroup C polysaccharide conjugate and serogroup B outer
membrane vesicle vaccine, and Brazil, which, beginning in 2011
has vaccinated infants with a serogroup C conjugate vaccine [55].
Meningococcal vaccines have also been used in other age groups
in response to outbreaks of IMD [61,62]. A case-control analysis
following administration of the serogroup C conjugate vaccine
following one of these outbreaks found an overall vaccine effec-
tiveness of 98% [63]. The effect of the vaccinewas also assessed in
the Federal District of Brazil where the overall incidence of IMD
was reduced by 68% and an 80% decline occurred in serogroup C
IMD after vaccine introduction [57].
Africa
The rate of meningococcal meningitis in regions of sub-
Saharan Africa greatly exceeds that occurring in other regions
of the world [64]. Meningococcal disease epidemics in the Afri-
can meningitis belt typically occur during the dry season from
January through June when the incidence can reach as high as
1,000 cases per 100,000 population. In periods between out-
breaks, the rate of endemic disease remains relatively high at 10
to 25 cases per 100,000 population [65]. In the decades between
1990 and 2010, the predominant serotype associated with out-
breaks in the meningitis belt has been serogroup A [66], with
speciﬁc sequence types causing many of the meningitis cases
[67,68]. This high incidence of serogroup A meningitis led to the
development of a serogroup A polysaccharide conjugate vaccine
(MACV) [69] that was administered in 2010 to nearly 100% of the
population of Burkina Faso between the ages of 1 and 29 years
[70]. Since that time, immunization campaigns with MACV have
been conducted in a number of countries within the meningitis
belt with generally high coverage rates reported [71e73]. In the
period between 1995 and 2004, an estimated 60,000 deaths
occurred during meningococcal outbreaks in this region [66]. In
2005, before the introduction of MACV, the CFR among countries
in the meningitis belt ranged from 4% in Mali to 26% in Benin
[66]. Since introduction of MACV, the overall CFR in the sur-
veillance countries has been relatively stable at 8.5%, 9.1%, and
9.1% in 2012, 2013, and 2014, respectively [71e73].
Widespread use of MACV has been accompanied by an overall
reduction in epidemic activity among countries in the meningitis
belt that have reported surveillance data [71,73]. In Burkina Faso,
more meningitis cases were reported during the 2012 meningitis
season than in the 2011 season, primarily because of an increase in
serogroupWcases [74]. In contrast, in regionsof ChadwhereMACV
was not used, serogroup A still predominated [75], demonstrating
the shift in serotypes in communities in countrieswith a successful
vaccination program. Among meningitis cases in 2012 through
2014 fromwhich the serogrouphas beendetermined,W is now the
most common serogroup (76%, 72%, and 81% of meningococcal
isolates identiﬁed) [71e73]. Analysis of serogroupW isolates from
cases in Niger in 2010 and 2011 and Burkina Faso in 2012 found a
single sequence type was dominant [74,76].
Although rare in other parts of the world, meningococcal
meningitis associated with serogroup X has been documented in
a number of African countries [77]. In 2006, serogroup X men-
ingitis outbreaks occurred in Niger, Kenya, and Uganda [77].
Although the incidence of serogroup X meningitis is still rela-
tively low, the number of cases, as well as the lack of an effective
vaccine, warrants continued surveillance of meningococcal
disease associated with this serogroup.Asia and Western Paciﬁc
The paucity of surveillance data from most countries in the
Asian and Western Paciﬁc regions makes conﬁdence in epide-
miologic trends in this area difﬁcult. In general, meningococcal
vaccines are not included in the NIPs of countries in this region.
In China, serogroup A was the predominant serogroup asso-
ciated with IMD until the early 2000s [78]. A serogroup A poly-
saccharide vaccine introduced in 1982 led to a stabilization of
IMD cases in China at .2 to 1 case per 100,000 population.
However, an increase in serogroup C cases in 2002/2003 led to a
vaccination program with a combined serogroup A/C poly-
saccharide vaccine in 2004. Data from the city of Hefei, in Anhui
Province, found that the incidence of IMD peaked in 2005 at 8.43
cases per 100,000 and then decreased to 2.32 cases in 2010.
There was a concomitant shift in the percentage of serogroup C
IMD cases from 83% in 2005 (with 13% of cases identiﬁed as
serogroup A) to 40% in 2010 (with 49% of cases identiﬁed as
serogroup A) [78]. The CFR of serogroup C IMD was roughly
double that of serogroup A IMD from 2000 to 2010.
Because IMD is rare in Japan, a study to assess the charac-
teristics of meningococcal isolates examined those collected
between 1974 and 2003 [79]. The predominant serogroups
among these isolates were serogroups B (57%) and Y (21%).
No meningococcal vaccines are currently approved for use in
Japan [80].
As in Japan, IMD is uncommon in Korea [81]. Data from iso-
lates collected from IMD cases in 2002/2003 found that
serogroup Y was the most common among this small sample
(9 of 11 isolates, 81.9%) [81]. Among 16 N. meningitidis isolates
collected from the cerebrospinal ﬂuid of children with bacterial
meningitis aged <5 years in Jeonbuk Province (2001/2002), nine
were serogroup X (56.3%) and six were serogroup Y (37.5%) [82].
Following an outbreak of IMD at a military training center in
2011, Korean authorities recommended that beginning in 2012,
new military recruits receive the quadrivalent ACWY conjugate
vaccine [83].
Beginning in 1994, Australia has conducted an annual survey
of IMD (the Australian National Neisseria Network). The number
of IMD cases recorded in the most recent National Neisseria
Network report (2013) was 143, the lowest number since the
surveillance system started. The number of IMD cases has been
declining in Australia since 2002, due in part, to the introduction
of the serogroup C conjugate vaccine to the NIP in 2003 (single
vaccination at 12 months of age with a catch-up program for
individuals aged 1e19 years) [84]. In 2002, serogroups B and C
accounted for 55.8% and 41.5% of IMD cases, respectively [85].
Most cases in 2013 were associated with serogroup B (72.7%)
with serogroup Y associated with 10.5% [86].
Similar to the situation in Australia, the incidence of IMD has
generally been declining in New Zealand since 2002 [87]. The
incidence of IMD in 2013 was 1.5 per 100,000 population, which
is the lowest it has been for 20 years. The predominant serogroup
in 2013 was serogroup B (52.6% of IMD cases), followed by
serogroup C (29.8%) [87]. A prolonged epidemic of IMD associ-
ated with serogroup B led to the development and administra-
tion (beginning in 2003) of a serogroup B outer membrane
vesicle vaccine speciﬁc for the endemic New Zealand strain [88].
Despite this restricted speciﬁcity, the high vaccine coverage
(83%) and effectiveness (77% vs. the unvaccinated population)
[89] are likely to have been factors in the decline of IMD rates
observed in New Zealand in recent years.
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The incidence of IMD is highest in infants aged <1 year and
remains relatively high until approximately age 5 years.
Although the incidence tends to decrease in older children, it
usually spikes again during adolescence and young adulthood
when individuals are living in close quarters. Incidence again
tapers off in older adults. This pattern has been observed at both
the regional [1,6,46,64] and country levels [1,5,30,44] and with
individual serogroups [27,45] (Figure 1). The CFR of IMD is
sometimes higher in infants than in older children [30,44,64] but
is routinely highest in adults aged 65 years [1,30,44,64,90,91].
As with IMD incidence levels, high CFRs among older adults are
observed when rates associated with individual serogroups are
examined [27,30].
General trends can also be observed when examining the
prevalence of serogroups in the various age groups. In North
America and Europe, serogroup B is the most common serogroup
associated with IMD in infants [1,5,6,27e29,44,46], with inci-
dence also routinely spiking during adolescence and young
adulthood [27,44,92] in the current era of universal immuniza-
tion with MenACWY in adolescents. Recent surveillance data
from Europe indicate that serogroup B is the causative agent for
at least 70% of IMD cases in all age groups up to 24 years [6]. The
proportion of IMD cases caused by serogroup B generally
declined with age but remained relatively high in individuals at
or older than 65 years.
There has been a substantial reduction in serogroup C IMD in
all age groups in the Netherlands [43,49] and in England and
Wales [45] after the introduction of the serogroup C vaccine. This
suggests that the protection of the older and/or nonvaccinated
population likely results from herd protection induced by the
vaccine [45,49]. Likewise, in the United States, the incidence of
IMD associated with serogroups C, W, and Y among the 11- to
19-year-old population has been declining since the introduction
of the quadrivalent vaccine [92].
In Europe, substantial increases in serogroup Y IMD have been
observed in the <1-, 1- to 4-, and 25- to 49-year age groups be-
tween 2008 and 2011 [6]. In England and Wales, the highest
incidence of serogroup Y IMD in 2009 was in those aged
15e19 years, 45e64 years, and 65 years [52]. Serogroup Y IMD
in theUnited States is typically seen in older individuals, although
cases in infants have become more common in recent years [93].
Meningococcal Carriage and the Effect of Vaccines
N. meningitidis is a common constituent of the human naso-
pharyngeal microbiota, and carriage is a necessary precursor to
the development of IMD. Although IMD rates are highest in in-
fants and young children, carriage rates typically peak in late
adolescence/young adulthood and then decline [22,94]. Recent
studies have found carriage rates of 4.5% in infants, 23.7% in those
aged 19 years, and 7.8% in 50-year olds in countries where
serogroups B and C were predominant (such as in Europe) [94].
Overall N. meningitidis carriage rates in 2012 among university
students in Chile were 4% [95]. In the African meningitis belt, the
carriage rate of N. meningitidis was 1.8% in infants, 4.9% for those
aged 5e14 years, and 2.6% for individuals 30 years [22]. Rela-
tively low N. meningitidis carriage rates of 3.2%e4.0% were found
in the U.S. states of Georgia and Maryland in 2006e2007 [96],
indicating the variations in carriage rates may be observed be-
tween different geographic areas. This is a substantial decreasecompared with a similar study conducted in Georgia in 1998 in
which the carriage rate was 6.1%e7.7% [97]. The high trans-
missibility of N. meningitidis is demonstrated by the rapid in-
crease in carriage rates when students begin living in university
dormitories [98,99] and in the acquisition of serogroup W in
pilgrims to the Hajj as well as in their household contacts [100].
Prevention of N. meningitidis serogroup C carriage and subse-
quent herd effect leading to reduction in IMD in unimmunized
individuals is an important beneﬁt of immunization programs.
The reduction in meningococcal carriage following vaccination
appears limited to the polysaccharide-conjugate formulations
and is rarely seen with polysaccharide-only formulation [101].
Administration of a meningococcal A/C polysaccharide vaccine
during anoutbreak in Brazil hadnoeffect onoverall carriage rates.
In contrast, meningococcal conjugate C (capsular polysaccharide-
protein) vaccines have routinely demonstrated a serogroup-
speciﬁc reduction in carriage. In the United Kingdom, adminis-
tration of the serogroup C conjugate vaccine led to a substantial
reduction in serotype C carriage in university students for up to
2 years after vaccine administration [102]. Conversely, the car-
riage rate of meningococcal serogroup Y has been increasing in a
cohort of university students in the United Kingdom [98]. In
Burkina Faso, carriage studies 2 years after widespread use of the
serogroup A conjugate vaccine have shown that carriage of
serogroup A has been nearly eliminated [98].Recent Meningococcal Outbreaks
The introduction and widespread use of meningococcal vac-
cines for serogroup C in Europe and for serogroups A, C, W, and Y
(with growing use in Europe) have led to reductions in IMD
associated with these serotypes. Until recently, the lack of a
vaccine targeting serogroup B has meant that individuals were
vulnerable to this pathogen. Accordingly, a number of outbreaks
caused by serogroup B have occurred in recent years. Because of
the contagious nature of N. meningitidis, these outbreaks often
occur among those interacting in classrooms, residence halls, or
the workplace.
The U.S. Centers for Disease Control and Prevention deﬁnes an
MnB organizational outbreak as one inwhichmore than one case
occurs that are “linked by a common afﬁliation other than a
shared, geographically delineated community” [103]. Since 2010,
there have been ﬁveMnB outbreaks (Table 1) in the United States
[104,107,108,110,111], one in Ireland [105], and one in the United
Kingdom [106]. The outbreaks in the United States, in which
2e10 conﬁrmed cases per outbreak were identiﬁed, have all
involved students at universities or contacts of those students.
Analysis of isolates from patients indicates that different MnB
clones (as determined by sequence type) were recovered from
several of the outbreaks [104,107,108,110,111].
The recent U.S. Food and Drug Administration approval of
vaccines for MnB and recommendations for use in 16- to 18-year
old individuals as well as during outbreak situationsmay serve to
prevent the morbidity and mortality resulting from MnB out-
breaks. MnB vaccines have been used (in consultation with the
U.S. Food and Drug Administration) before approval in some of
the U.S. outbreaks described here [108,109] and were associated
with halting of the outbreak. Laboratory analysis indicates that
antisera from subjects vaccinated with bivalent rLP2086 are
bactericidal for MnB isolates from recent university outbreaks in
the United States [112], and pooled sera from adolescents and
Table 1
Invasive meningococcal disease outbreaks associated with serogroup B since 2010
Location Dates Number of cases Serotypes/clonal complexes Reference
Ohio, USA January 2008eNovember 2010 10 ST-269/ST-269 [104]
Irelanda March 2010eNovember 2013 8 ST-6697/ST-41/44 [105]
Warwickshire, UKa February 2013eJune 2013 5 ST-1194/ST-41/44 [106]
New Jersey, USAa March 2013eMarch 2014 8 ST-409/ST-41/44 [107]
California, USA November 2013 4 ST-32/ST-32 [108]
Oregon, USA January 2015 7 Not available [109]
Rhode Island, USA February 2015 2 ST-9069 [110]
a Associated with the same sequence type serogroup B strain.
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associated with recent IMD outbreaks worldwide [113].
Outbreaks of serogroup C disease in men having sex withmen
have been reported since 2013 in three European countries:
Germany, France, and Belgium [114]. This strain is related to the
outbreak strain identiﬁed in New York City from 2010 to 2013.
Most recently, eight cases of meningococcal disease have been
reported from the United Kingdom and Sweden in youth
returning from the 23rdWorld Scout Jamboree and their contacts
[115]. In two of the cases in the United Kingdom, a serogroup W
strainwas isolated as the causative agent andwhich is identical to
a strain already circulating in the that country.
Two large outbreaks of meningococcal serogroup C IMD are
currently occurring in Africa. Between January and May 2015,
Niger’s Ministry of Public Health notiﬁed the World Health
Organization of 8,500 suspected cases of meningococcal men-
ingitis, including 573 deaths [116]. This is the ﬁrst large-scale
meningitis outbreak caused by N. meningitidis serogroup C to
hit any country in Africa’smeningitis belt. During a similar period
(January 2015 through March 2015), Nigeria notiﬁed the World
Health Organization of 652 suspected cases of meningococcal
disease, including 50 deaths, apparently due to serogroup C [117].
Both of these outbreaks emphasize the potential for serotype
shifts following introduction of meningococcal conjugate
vaccines with limited coverage of clinically relevant isolates.Summary and Future Considerations
Studies of the epidemiology of meningococcal disease demon-
strate signiﬁcant differences in serogroup distributions by
geographic regions. The introduction of MenCC vaccines in Europe,
MenACWY in the United States and Canada, and MACV in Africa
appear to be associated with declines in vaccine type disease and
shifts in serotype distributions in those geographic regions.
Serogroup B has become the major cause of outbreaks as well as
endemic disease in Europe and North America. Serogroup X andW
demonstrate increasing importance in Africa and serogroup Y is
more prevalent in Scandinavia and United Kingdom.
Regional epidemiologic considerations have guided the
development and use of meningococcal vaccines, which have
been effective in the serogroup-speciﬁc reduction of IMD in areas
where those vaccines have been used. Although evidence of
capsular switching has not been extensive thus far, an increased
prevalence of serogroups either not covered in existing vaccines
(e.g., serogroup X in Africa) or contained in vaccines that are not
in common use (e.g., serogroup Y in Europe) has been observed.
Because infants, adolescents, and young adults are a population
at increased risk for IMD, and serogroup B is one of the most
predominant serogroups in the United States, the recentlyapproved MnB vaccines are particularly applicable to these age
groups. The MnB vaccine licensed in the European Union was
added to the NIP of England in September 2015 [118]. Epidemi-
ologic surveillance will continue to be important in providing
data on which national and regional health authorities can base
vaccination policies. Further reductions in the morbidity and
mortality associated with IMD may be achieved with the intro-
duction of serogroup appropriate vaccines informed by epide-
miologic data.
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